Compare Genuine Parts Company (GPC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs IDEXX Laboratories, Inc. — how do they compare? Genuine Parts Company trades at $135.22 (market cap $18.62B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.5× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.15% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GPC | IDXX | |
|---|---|---|
Market Cap | $18.62B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $766.68 |
52-Week Low | $92.47 | $526.44 |
Enterprise Value | $24.72B | $47.12B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $133.89, down 0.48% today, with a bullish technical outlook from moving averages but overbought RSI signals. Recent Q2 2026 earnings beat expectations with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The company maintains a dividend payout, with a $1.06 dividend declared for H1 2026. Valuation shows a high P/E of 540.36 but a reasonable P/S of 0.75, while net income margins remain thin at 0.13% for 2025.
Outlook is mixed: analyst consensus targets $148.67 with 43% buy ratings, but profitability challenges and rising debt-to-asset ratios pose risks. The stock's proximity to its 52-week high suggests limited near-term upside, requiring careful monitoring of margin improvements and industrial segment performance to justify further gains.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
